Alex Denoon and Erik Vollebregt analyse the post-marketing surveillance obligations introduced in March.
Post-marketing surveillance (PMS) obligations introduced in March 2010 for medical devices have attracted relatively little comment, but efforts by manufacturers to comply with them can be significant...
Please login to read the full article.
